Alexandria Real Estate Equities, Inc. (NYSE:ARE)

CAPS Rating: No stars

The Company is engaged principally in the ownership, operation, management, selective redevelopment, development and acquisition of properties for the life sciences industry.

ARE News and Commentary

Caps

How do you think ARE will perform against the market?

Add Stock to CAPS Watchlist

All Players

80 Outperform
51 Underperform
 

All-Star Players

22 Outperform
9 Underperform
 

Wall Street

12 Outperform
0 Underperform
 

Top ARE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFMattyA (99.83)
Submitted September 17, 2013

Alexandria Real Estate Equities (ARE) is the largest “life science” real estate company, serving major pharmaceutical, biotech, and medical sciences industries. At the end of 2012, ARE owned 178 properties, covering about 17 million rent-able square… More

Ewok82 (28.83)
Submitted May 25, 2009

Expensive property in a niche market for life science research seems to be a bit speculative in this market, especially given that some of these properties are in cities like SF, where prices continue to fall as taxes continue to rise.

ARE VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ARE.

Recs

4
Member Avatar TMFMattyA (99.83) Submitted: 9/17/2013 3:16:52 PM : Outperform Start Price: $55.11 ARE Score: +71.51

Alexandria Real Estate Equities (ARE) is the largest “life science” real estate company, serving major pharmaceutical, biotech, and medical sciences industries. At the end of 2012, ARE owned 178 properties, covering about 17 million rent-able square feet that were 93.4% leased. They own some of the largest life science properties in New York City, Boston, San Diego and Research Triangle Park in North Carolina.

ARE has crushed the market over the long-term and currently yields over 4%. REITs have been hit pretty bad lately with the recent rise in Treasury yields, so you're getting ARE at a bargain today. I think it's not only an exceptionally-managed REIT, but a great way to indirectly bet on biotech (without a lot of the additional risk).

Recs

1
Member Avatar Ewok82 (28.83) Submitted: 5/25/2009 12:49:11 PM : Underperform Start Price: $24.69 ARE Score: -201.25

Expensive property in a niche market for life science research seems to be a bit speculative in this market, especially given that some of these properties are in cities like SF, where prices continue to fall as taxes continue to rise.

Recs

0
Member Avatar crabbucket1 (< 20) Submitted: 5/7/2009 9:29:24 AM : Outperform Start Price: $27.15 ARE Score: +156.85

Cheap for the long haul @ <36.00....Too good to pass on for a 1yr term....Project to make 20-25% in 10-12 months...

Leaderboard

Find the members with the highest scoring picks in ARE.

Score Leader

SSPX3

SSPX3 (< 20) Score: +220.17

The Score Leader is the player with the highest score across all their picks in ARE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
SSPX3 < 20 5/14/2009 Outperform NS $23.83 +412.98% +192.81% +220.17 0 Comment
czarl 21.07 5/27/2009 Outperform NS $27.17 +349.99% +184.13% +165.86 0 Comment
TraderJFH 94.77 7/22/2009 Outperform 1Y $28.61 +327.35% +169.85% +157.50 0 Comment
crabbucket1 < 20 5/4/2009 Outperform 3M $27.15 +350.24% +193.39% +156.85 1 Comment
NSHanlon 44.12 4/27/2009 Outperform 3Y $27.79 +339.90% +203.23% +136.67 0 Comment
mitchiemono 78.11 4/27/2009 4/24/2010 Outperform 3Y $27.79 +339.90% +203.23% +136.67 0 Comment
SSPXXX 84.51 6/8/2009 Outperform 5Y $30.98 +294.70% +176.84% +117.86 0 Comment
Lance03 96.69 3/9/2009 Outperform NS $24.32 +402.73% +285.05% +117.67 0 Comment
TMFMattyA 99.83 9/17/2013 Outperform 5Y $55.11 +121.85% +50.33% +71.51 1 Comment
BaseBawl 22.69 10/4/2013 Outperform 5Y $55.65 +119.68% +52.79% +66.89 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.96 8/2/2016 Outperform 3W $105.54 +15.84% +19.28% -3.44 0 Comment
TrackZacks < 20 2/23/2012 Underperform 3M $70.56 +0.58% -2.58% -3.16 6/8/2012 @ $70.97 1 Comment
TrackRBCCapMkts 88.39 6/21/2011 Outperform NS $63.85 +91.48% +100.30% -8.83 0 Comment
TrackGoldmanSach 77.11 12/20/2010 Outperform 5Y $55.55 +120.08% +106.28% +13.80 1 Comment
TrackBarclaysCap 91.80 3/4/2010 Outperform NS $49.17 +148.63% +128.64% +19.98 0 Comment
TrackDreman 75.70 9/30/2009 Outperform NS $42.48 +187.84% +150.89% +36.94 0 Comment
TrackRWBaird 90.29 9/1/2009 Outperform NS $43.38 +181.86% +152.36% +29.50 0 Comment
TrackJMP 84.66 8/4/2009 Outperform NS $30.74 +297.70% +158.37% +139.33 0 Comment
TrackUBS 91.79 9/17/2008 Outperform NS $79.07 +54.63% +121.64% -67.01 0 Comment
TrackChrisDavis 96.00 6/3/2008 Outperform 1Y $75.11 +62.78% +91.41% -28.63 1 Comment
TrackRonBaron 77.43 3/31/2008 Outperform NS $67.67 +80.67% +102.04% -21.37 1 Comment
TrackHeebner 23.38 12/31/2007 Outperform NS $73.58 +66.16% +83.27% -17.11 3 Comments
TrackCantorFitz 34.15 1/31/2007 Outperform NS $74.96 +63.09% +91.34% -28.24 0 Comment
TrackRBCCapMkts 88.39 11/7/2006 Underperform NS $83.56 -5.36% -7.08% -1.72 6/21/2011 @ $79.08 0 Comment
TrackRyanBeck < 20 10/26/2006 Outperform NS $86.60 +7.17% -6.02% +13.20 3/1/2007 @ $92.81 0 Comment

Featured Broker Partners